US Bancorp
MGX icon

US Bancorp’s Metagenomi Therapeutics MGX Stock Holding History

US Bancorp’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.03K Hold
4,500
– – ﹤0.01% 3517
2025
Q4 		$7.29K Hold
4,500
– – ﹤0.01% 3427
2025
Q3 		$10.7K Hold
4,500
– – ﹤0.01% 3295
2025
Q2 		$6.66K Hold
4,500
– – ﹤0.01% 3550
2025
Q1 		$6.12K Hold
4,500
– – ﹤0.01% 3596
2024
Q4 		$16.2K Hold
4,500
– – ﹤0.01% 3241
2024
Q3 		$9.77K Hold
4,500
– – ﹤0.01% 3370
2024
Q2 		$18.4K Hold
4,500
– – ﹤0.01% 3102
2024
Q1 		$47.5K Buy
+4,500
New +$51.7K ﹤0.01% 2730

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

US Bancorp's MGX Position: Q1 2026 in Review

US Bancorp held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 4,500 shares worth $6.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

US Bancorp first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $47.5K in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • US Bancorp held 4,500 shares of Metagenomi Therapeutics worth $6.03K as of Q1 2026.
  • US Bancorp left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3517 holding.
  • US Bancorp first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • US Bancorp's Metagenomi Therapeutics position peaked at $47.5K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.